---
id: 059
title: Polymyxin Nephrotoxicity and Neurotoxicity
category: antimicrobials
subcategory: polymyxins
tags: [colistin, polymyxin-B, nephrotoxicity, neurotoxicity, AKI, monitoring]
difficulty: hard
---

## Question

What are the **major toxicities** of polymyxins (colistin and polymyxin B), and how should they be monitored? Use the **"NEPHRO-NEURO Toxicity"** mnemonic.

## Answer

### **"NEPHRO-NEURO Toxicity" Mnemonic:**

**NEPHRO (Nephrotoxicity - MOST COMMON):**
- **N**ephrotoxicity 40-60% incidence
- **E**levated creatinine (monitor daily)
- **P**olymyxins damage renal tubules
- **H**igh risk: elderly, baseline CKD, other nephrotoxins
- **R**eversible in 80-90% if stopped early
- **O**ccurs median 5-7 days after start

**NEURO (Neurotoxicity - RARE):**
- **N**eurotoxicity 0-7% incidence
- **E**xtremity paresthesias (tingling)
- **U**sually mild and reversible
- **R**arely: seizures, ataxia, confusion
- **O**ccurs early (days 1-5)

### **Nephrotoxicity (Most Limiting Toxicity):**

#### **Incidence (2024 Data):**

| Agent | AKI Incidence | Notes |
|-------|---------------|-------|
| **Colistin (CMS)** | 40-52% | Possibly higher than polymyxin B |
| **Polymyxin B** | 35-45% | Possibly lower than colistin |
| **Overall polymyxins** | 40-60% | Dose and duration dependent |

**Time to Onset:** Median 5-7 days (range 2-14 days)

#### **Risk Factors for Polymyxin-Associated AKI:**

| Risk Factor | Impact | Notes |
|-------------|--------|-------|
| **Age >60 years** | High risk | Reduced GFR baseline |
| **Baseline CKD** (CrCl <60) | **Highest risk** | Pre-existing dysfunction |
| **Concurrent nephrotoxins** | High risk | Vancomycin, aminoglycosides, NSAIDs |
| **High cumulative dose** | Dose-dependent | Shorten duration when possible |
| **ICU admission** | Increased risk | Multiorgan dysfunction |
| **Septic shock/vasopressors** | Increased risk | Hypoperfusion |

#### **Monitoring Protocol:**

**Baseline:**
- Serum creatinine, BUN
- Calculate CrCl (Cockcroft-Gault)
- Review medication list (identify nephrotoxins)

**During Therapy:**
- **Daily serum creatinine** (first week)
- **Every 2-3 days** if stable after first week
- **Urinalysis** if concern for ATN
- Monitor urine output

**Discontinuation Criteria:**
- **AKI Stage 2-3** (Cr increase ≥2× baseline or SCr ≥4.0 mg/dL)
- Rising Cr despite dose adjustment
- Consider stopping if alternatives available

#### **Reversibility:**
- **80-92% reversible** with drug discontinuation
- Time to recovery: 7-21 days (median 10 days)
- Polymyxin B: 79% reversible
- Colistin (CMS): 91.6% reversible

### **Neurotoxicity (Less Common):**

#### **Incidence:** 0-7% (mostly mild)

**Clinical Manifestations:**

| Symptom | Frequency | Severity |
|---------|-----------|----------|
| **Paresthesias** (hands, feet, face) | Most common | Mild |
| **Dizziness, vertigo** | Common | Mild |
| **Muscle weakness** | Uncommon | Moderate |
| **Confusion, hallucinations** | Rare | Severe |
| **Seizures** | Rare | Severe |
| **Neuromuscular blockade** | Very rare | Life-threatening |
| **Ataxia** | Rare | Moderate |

**2024 Data:**
- Polymyxin B: 13/77 patients (16.9%) - mainly paresthesias
- Colistin (CMS): 1/70 patients (1.4%)
- **All events reversible** after discontinuation

**Timing:** Early onset (days 1-5)

**Risk Factors:**
- Renal impairment (accumulation)
- High doses
- Rapid IV administration
- Concurrent neurotoxic drugs

## Key Points

### **Colistin vs Polymyxin B Toxicity (2024 Comparison):**

| Toxicity | Colistin (CMS) | Polymyxin B | Winner |
|----------|----------------|-------------|--------|
| **Nephrotoxicity** | 40-52% | 35-45% | **Polymyxin B** (possibly lower) |
| **Neurotoxicity** | 0-7% (lower) | 0-7% (possibly higher) | **Colistin** |
| **Reversibility (nephro)** | 91.6% | 79% | **Colistin** |
| **PK predictability** | Variable (prodrug) | Predictable | **Polymyxin B** |

**Note:** Differences may not be statistically significant; studies show conflicting results

### **Dose Adjustments in Renal Impairment:**

**Colistin (CMS):**

| CrCl (mL/min) | Loading Dose | Maintenance Dose |
|---------------|--------------|------------------|
| **≥80** | 300 mg CBA | 300 mg CBA q12h or 200 mg q8h |
| **50-79** | 300 mg CBA | 200-230 mg CBA q12h |
| **30-49** | 200 mg CBA | 130-150 mg CBA q12h |
| **10-29** | 200 mg CBA | 100-130 mg CBA q24-36h |
| **HD/CRRT** | 200 mg CBA | Per protocol (dialyzable) |

**Polymyxin B:**
- Standard: 15,000-25,000 units/kg/day divided q12h
- **No official dose adjustment** for renal impairment (conflicting guidance)
- Some experts reduce dose 50% if CrCl <30

### **Management of Toxicity:**

**Nephrotoxicity:**
- **Minimize concomitant nephrotoxins** (stop if possible)
- Ensure adequate hydration
- Consider dose reduction
- If AKI severe (Stage 2-3): **Discontinue polymyxin**
- Alternative: Switch to different class if susceptible

**Neurotoxicity:**
- **Usually mild and self-limited**
- Slow IV infusion (over 1-2 hours)
- Dose reduction if renal impairment
- If severe (seizures, NM blockade): **Discontinue immediately**

### **Clinical Pearls:**
- **Nephrotoxicity is dose-limiting toxicity** (most common reason to stop)
- **Daily Cr monitoring essential** in first week
- **Avoid combination** with vancomycin, aminoglycosides if possible
- **Reversibility high** if caught early (80-90%)
- **Shorten duration** to minimum effective (reduces cumulative toxicity)
- Polymyxin B may have slightly **lower nephrotoxicity** than colistin
- **All neurotoxic events reversible** with drug withdrawal

## Sources

- [BMC Infect Dis 2024: Polymyxin B vs Colistin Neurotoxicity and Nephrotoxicity]
- [PMC3224475: Renal and Neurological Side Effects of Colistin]
- [Ann Clin Microbiol 2018: Colistin vs Polymyxin B Nephrotoxicity Comparison]
- [Frontiers Pharmacology 2024: Polymyxins Recent Advances]

## Media

N/A
